Australie - anglais - Department of Health (Therapeutic Goods Administration)

gutbiome aust pty ltd - lactobacillus acidophilus, quantity: 333.3 million cfu/g; lactobacillus delbrueckii ssp bulgaricus, quantity: 66.7 million cfu/g; lactobacillus brevis, quantity: 66.7 million cfu/g; lactobacillus casei, quantity: 300 million cfu/g; bifidobacterium animalis ssp lactis, quantity: 666.7 million cfu/g; lactobacillus paracasei, quantity: 333.3 million cfu/g; lactobacillus rhamnosus, quantity: 3.333 billion cfu/g; lactobacillus plantarum, quantity: 500 million cfu/g; lactobacillus salivarius ssp salivarius, quantity: 66.7 million cfu/g; lactobacillus reuteri, quantity: 33.3 million cfu/g; lactobacillus gasseri, quantity: 33.3 million cfu/g; bifidobacterium bifidum, quantity: 66.7 million cfu/g; bifidobacterium breve, quantity: 66.7 million cfu/g; bifidobacterium lactis, quantity: 666.7 million cfu/g; bifidobacterium longum, quantity: 66.7 million cfu/g; bifidobacterium infantis, quantity: 100 million cfu/g; streptococcus thermophilus, quantity: 200 million cfu/g; saccharomyces cerevisiae (boulardii), quantity: 833.3 million cfu/g; actinidia chinensis, quantity: 185 mg/g - powder, oral - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; glycine; silicon dioxide - maintain/support general health and wellbeing ; decrease/reduce/relieve diarrhoea ; helps reduce occurrence of symptoms of traveller's diarrhoea ; maintain/support healthy bowel/colon function ; maintain/support small intestine health ; maintain/support intestinal health ; maintain/support healthy digestive system function ; maintain/support digestion/assimilation of nutrients ; maintain/support digestive system health ; maintain/support good/beneficial/friendly bacteria adherence to intestinal mucosa ; maintain/support intestinal good/beneficial/friendly flora ; helps maintain/support good/beneficial/friendly gut flora during antibiotic use ; help restore good/beneficial/friendly gut flora after antibiotic use ; helps restore good/beneficial/friendly intestinal/gut/bowel flora ; helps enhance/improve/promote/increase healthy digestive system flora/good bacteria growth ; helps enhance/improve/promote/increase intestinal good/beneficial/friendly bacteria growth ; maintain/support small intestine good/beneficial/friendly flora ; maintain/support gastrointestinal system health ; helps enhance/promote gastrointestinal system health ; maintain/support healthy gastrointestinal function ; maintain/support gastrointestinal mucosal membrane health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy gastrointestinal immune function ; helps reduce occurrence of symptoms of upper respiratory tract infections

Canada - anglais - Health Canada

glaxosmithkline inc - haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) - powder for solution - 10mcg - haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) 10mcg - vaccines

Australie - anglais - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 7.45 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sodium citrate; purified talc; guar gum; silicon dioxide; aspartame; citric acid; flavour - treatment of the following infections when caused by curam 125/31.25 sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing staph. aureus, e. coli and klebsiella sp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis and klebsiella sp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h. influenzae and m. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and staph. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h. influenzae and m. catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam 125/31.25. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of curam 125/31.25.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

nutrivital pty ltd - lactobacillus plantarum, quantity: 12.79 billion cfu/g; lactobacillus rhamnosus, quantity: 15.88 billion cfu/g; lactobacillus casei, quantity: 11.46 billion cfu/g; lactobacillus paracasei, quantity: 16.5 billion cfu/g; lactobacillus gasseri, quantity: 1.88 billion cfu/g; lactobacillus reuteri, quantity: 670 million cfu/g; lactobacillus acidophilus, quantity: 11.17 billion cfu/g; lactobacillus delbrueckii ssp bulgaricus, quantity: 670 million cfu/g; bifidobacterium animalis ssp lactis, quantity: 6.06 billion cfu/g; bifidobacterium breve, quantity: 2.96 billion cfu/g; bifidobacterium longum, quantity: 1.88 billion cfu/g; bifidobacterium animalis ssp lactis, quantity: 2.69 billion cfu/g; bifidobacterium infantis, quantity: 1.08 billion cfu/g; streptococcus thermophilus, quantity: 4.31 billion cfu/g; inulin, quantity: 150 mg/g - powder, oral - excipient ingredients: colloidal anhydrous silica; maltodextrin - maintain/support general health and wellbeing ; maintain/support intestinal health ; maintain/support intestinal good/beneficial/friendly flora ; maintain/support gastrointestinal system health ; maintain/support gastrointestinal mucosal membrane health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy gastrointestinal immune function

Australie - anglais - Department of Health (Therapeutic Goods Administration)

b pure australia pty ltd - hydrolysed collagen, quantity: 987 mg/g; lactobacillus acidophilus, quantity: 1.8 billion cfu/g; lycopene, quantity: 3 mg/g - powder - excipient ingredients: rice bran - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support collagen formation ; maintain/support collagen health ; maintain/support general health and wellbeing ; maintain/support healthy digestive system function ; maintain/support digestive system health ; maintain/support gastrointestinal system health ; maintain/support healthy gastrointestinal function

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - rotavirus g2 human-bovine reassortant, quantity: 1400000 infectious unit/ml; rotavirus g3 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g1 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g4 human-bovine reassortant, quantity: 1000000 infectious unit/ml; rotavirus p1 [8] human-bovine reassortant, quantity: 1150000 infectious unit/ml - oral liquid - excipient ingredients: polysorbate 80; sucrose; sodium citrate dihydrate; sodium hydroxide; monobasic sodium phosphate; glucose monohydrate; sodium ascorbate; sodium chloride; ammonium metavanadate; calcium chloride dihydrate; cupric sulfate pentahydrate; ferric nitrate nonahydrate; ferrous sulfate heptahydrate; magnesium chloride hexahydrate; dried magnesium sulfate; manganese sulfate tetrahydrate; ammonium molybdate; potassium chloride; sodium acetate; sodium bicarbonate; dibasic sodium phosphate; zinc sulfate heptahydrate; alanine; arginine hydrochloride; asparagine; aspartic acid; cysteine hydrochloride; cystine dihydrochloride; glutamic acid; glycine; histidine hydrochloride monohydrate; hydroxyproline; isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine disodium; valine; biotin; ergocalciferol; choline chloride; folic acid; inositol; menadione; nicotinamide; nicotinic acid; aminobenzoic acid; calcium pantothenate; pyridoxal hydrochloride; pyridoxine hydrochloride; retinol acetate; riboflavine; dl-alpha-tocopheryl phosphate disodium; thiamine hydrochloride; cyanocobalamin; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine monophosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride; sodium hypoxanthine; linoleic acid; alpha lipoic acid; phenolsulfonphthalein; putrescine dihydrochloride; sodium pyruvate; ribose; thymidine; thymine; uracil; sodium xanthine; monoethanolamine; 2-mercaptoethanol; adenosine; uridine; cytidine; guanosine; dexamethasone; epidermal growth factor; hydrocortisone; insulin; alprostadil; liothyronine; ascorbic acid; magnesium sulfate heptahydrate; monobasic sodium phosphate monohydrate; zinc sulfate; arginine; cysteine; cystine; histidine; lysine; tyrosine; adenosine triphosphate; guanine; putrescine - rotateq is indicated for the prevention of rotavirus gastroenteritis (see clinical trials).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 57.8 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; colloidal anhydrous silica; sunset yellow fcf; sodium citrate dihydrate; xanthan gum; saccharin sodium; flavour - indications: treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 28.9 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: saccharin sodium; sorbitol; colloidal anhydrous silica; xanthan gum; sunset yellow fcf; sodium citrate dihydrate; flavour - indications: treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.